Local 'Shwartzman equivalent' reaction in active chronic hepatitis

MICHAEL J. WHELTON

From the Department of Medicine, Royal Free Hospital, London

SUMMARY The development of a purpura-fulminans-like disorder which is a human equivalent of a local Shwartzman reaction in a woman with active chronic hepatitis is described. The cyclical appearance of blue-black, well circumscribed, haemorrhagic, acutely painful lesions in the buttocks, over the lateral aspects of the thighs, and on the arms suggested the diagnosis. Evidence of increased intravascular coagulation was obtained although interpretation of clotting factor deficiencies in the presence of parenchymal liver disease was difficult. Treatment with heparin arrested the disorder on three separate occasions. The reasons for the development of the syndrome are not clear and even more surprising was the occurrence of such a disorder in the presence of increased fibrinolysis. While disseminated intravascular coagulation has been described in association with liver disease, the development of features of purpura fulminans in such patients does not appear to have been noted.

The Shwartzman reaction is an experimental animal entity which may be local or general. The local Shwartzman reaction is confined to a prepared tissue site, usually the skin. Local injection of a 'preparing' agent (classically Gram-negative endotoxin) followed 24 hours later by intravenous injection of a 'provoking' agent leads to intravascular coagulation with haemorrhagic necrosis of the prepared site. In the generalized Shwartzman reaction two intravenous injections of Gram-negative endotoxin 24 hours apart lead to intravascular coagulation with resultant fibrin thrombi and renal cortical necrosis (Hjort and Rapaport, 1965). Human disorders resembling Shwartzman reactions in animals have been termed 'Shwartzman equivalent' states (Colman and Rodriguez-Erdman, 1970). A patient with active chronic hepatitis who developed a clinical syndrome with features of a local Shwartzman reaction which was reversed by heparin therapy is described.

Case History

In June 1966 this 21-year-old Caucasian woman was first seen at the Royal Free Hospital where a diagnosis of active chronic hepatitis was made. At the age of 16 years she had been found to have a macrocytic anaemia (haemoglobin 11 g; MCV 125 cmm; MCHC 31%) and had been treated with vitamin B12, folic acid, and iron. Thrombocytopenia (platelets 80,000/cmm), primary amenorrhoea, and hepatosplenomegaly were also present at that time and had persisted over the ensuing five years. On 17 July 1966 she was admitted, as an emergency, to hospital with a one-week history of ankle oedema and painful, tender swellings in both buttocks and the anterior abdominal wall. There was no history of recent trauma, infection, or contact with any infectious disease. Haematoma formation was evident in the buttocks and anterior abdominal wall, the spleen was palpable, and there was striae formation, finger clubbing, and leuconychia. Following admission she developed congestive cardiac failure after a period of oliguria. A large, superficial haematoma appeared on the left thigh.

INVESTIGATIONS

Haematological
Haemoglobin 10:6 g/100 ml; reticulocytes 2:6%; platelets 44,000/cmm; white cell count 7,300/cmm; sedimentation rate 9 mm in the first hour; bone marrow showed megakaryocytes but no platelet budding.

Non-haematological
Serum total bilirubin 1:2 mg/100 ml; conjugated 0:8 mg/100 ml; alkaline phosphatase 15 K.A. units; total proteins 4:1 g/100 ml (albumin 2:1 g/100 ml);
serum cholesterol 115 mg/100 ml. A hepatic scinti-
scan showed a small liver with much uptake in the
spleen, features consistent with a diagnosis of hepatic
cirrhosis.

PROGRESS REPORT
Five days after admission the patient’s condition
became critical with widespread painful haematomas
forming over the arms, legs, and trunk (see Figure).
She was given a platelet infusion (concentrate
prepared from four donors); hydrocortisone 100 mg
intravenously and started on prednisolone 60 mg
daily. Her condition worsened and she developed
hepatic precoma requiring treatment with protein
restriction and neomycin. Results of coagulation
studies carried out during the sixth and seventh
days are summarized in the Table. There was also some
evidence for fibrinolysis as shown by the plasminogen
level of 1:4 Sherry-casein units (control 5 Sherry-
casein units); the presence of fibrin breakdown
products to a titre of 1:16 and a fibrinolysis titre
showing lysis at six hours, to a titre of 1:8 (control
1:64). This was not corrected in vitro by the addition
of epsilon amino caproic acid.

A diagnosis of disseminated intravascular coagula-
tion with features of the Shwartzman reaction was
made. The patient was started on continuous intra-
venous heparin at an initial dose of 18,000 units
followed by 3,000 units hourly. Additional therapy
consisted of fibrinogen 5 g; 2 units of packed red
cells; ampicillin 250 mg six hourly; and prednisolone
was continued at 40 mg daily. Haemorrhagic lesions
present ceased to enlarge and new lesions, which
continued to appear over the next 48 hours, did not
progress in size. All faded rapidly. The patient’s
general condition gradually improved. On the
seventh day of heparin therapy she had a small
haematemesis and the heparin was discontinued.
No further haemorrhagic lesions occurred and she
returned to her pre-bleeding state uneventfully.
Tissue loss was restricted to an area over the left
thigh in the region illustrated in the Figure. Two
further similar episodes occurred in January and
July 1967. In both instances heparin therapy was
promptly instituted and the patient made a rapid
recovery. On one of these occasions cephaloridin
was given since the episode was preceded by a mild
upper respiratory tract infection. She died in
hepatic failure with no evidence of bleeding diathesis
after 18 months of follow up. Necropsy was refused.

Discussion
Disseminated intravascular coagulation is increasingly
being recognized as an underlying bleeding state
which occurs in a wide variety of clinical situations.
Local ‘Shwartzman equivalent’ reaction in active chronic hepatitis

The term describes any condition in which depletion of clotting factors I, II, V, VIII, and platelets occurs, with or without compensatory fibrinolysis and regardless of the mechanism by which the clotting system has been activated (Colman and Rodriguez-Erdman, 1970). Likewise a considerable number of human ‘Shwartzman equivalent’ states have been described (Ackerman, 1942; McKay, Merrill, Weiner, Hertig, and Reid, 1953; McKay, Jewett, and Reid, 1959; Hardaway, Husni, Geever, Hjort and Rapaport, 1965; Moncrieff and Glasgow, 1970). Disease states resembling both a general and local Shwartzman reaction may occur and in the human, unlike the rabbit, distinction is often difficult. The present patient had many features characteristic of purpura fulminans, a human equivalent of a local Shwartzman reaction. Purpura fulminans usually occurs in children one to four weeks after an infectious preparatory disease (Hjort, Rapaport, and Jorgensen, 1964; Antley and McMillan, 1967) associated with leucocytosis, thrombocytopenia, and evidence of intravascular coagulation.

Several days elapsed before the diagnosis of disseminated intravascular coagulation was made in this patient. Initially, it was thought that the bleeding tendency was a manifestation of thrombocytopenia and parenchymal liver disease. The bone marrow result raised the possibility of idiopathic thrombocytopenic purpura but hypersplenism and systemic lupus erythematosus were also considered. Treatment with platelet concentrates and corticosteroids on the fifth day after admission failed to produce a favourable response and, indeed, her condition worsened. The presence of a circulating anticoagulant of the heparin type was suspected but disproved.

The skin lesions were typical of purpura fulminans. The lesions were dark blue, well circumscribed, and appeared in a cyclical fashion. They were extremely painful and in some instances underwent necrosis with subsequent tissue damage. Clotting factors were in keeping with a state of intravascular consumption coagulopathy although interpretation was difficult due to underlying liver disease which of itself may lower vitamin K-dependent factors, namely, factors II, VII, IX, and X in addition to factor V and platelets.

During her ‘normal’ periods, between episodes of intravascular coagulation, she had intermittently low levels of factor II, V, and fibrinogen but normal levels of factor VIII (Table I). Her platelet count had been low for five years. During her attacks, factors II and V fell further as did fibrinogen and platelets, whilst factor VIII fell but remained within normal limits (Table I). Improvement in the levels of all these factors followed recovery from each episode of intravascular coagulation. Recovery seemed to occur only after the introduction of heparin therapy although the administration of antibiotics concomitantly may have played some part. Corticosteroid therapy alone appeared to have no beneficial effect and indeed the patient’s condition worsened following the introduction of this treatment. It is of interest that on the third occasion we treated this patient she had an actual rise of factor VIII to 150% before treatment, the level reverting to normal after heparin therapy. A similar finding has been reported by Zetterqvist and Von Franken (1963).

The occurrence of disseminated intravascular coagulation in patients with liver disease has been reported by several authors (Zetterqvist and Von Franken, 1963; Johansson, 1964; Rake, Flute, Pannell, and Williams, 1970). Manifestations of a local Shwartzman reaction do not appear to have occurred in these patients. The presence of consumption coagulopathy alone, however, is insufficient for the development of the Shwartzman reaction, other modifying factors, particularly defective fibrinolysis, being necessary (Colman and Rodriguez-Erdman, 1970). The pathogenesis underlying the acute illness in the present patient is unknown as is the role of her liver disease. Increased, rather than decreased, fibrinolytic activity has been described in many forms of liver disease (Von Kaulla, 1963) though it is poorly correlated with clinical bleeding disorders in such patients. The present patient also had some evidence of increased fibrinolysis. Although a mild infection did precede one episode, there was no other evidence to suggest endotoxic shock nor was she gravid during any of her attacks.

The clinical features, course, and response to heparin were fully consistent with a diagnosis of purpura fulminans, a human equivalent of a local Shwartzman reaction. Heparin therapy prevents the experimental Shwartzman reaction (Good and Thomas, 1953) and there is good evidence of its value in human equivalent states (Hjort and Rapaport, 1965). Corticosteroids potentiate the Shwartzman reaction and, while they may be necessary to combat shock, should probably only be administered in addition to heparin where this syndrome is suspected.

The difficulty of diagnosis in patients with cirrhosis who develop a bleeding diathesis has been mentioned and in this patient the diagnosis was not made for several days. The possibility of disseminated intravascular coagulation should be considered in patients with both acute and chronic liver disease who develop a bleeding diathesis with unusual features. Therapy with heparin in an established case, is logical, and, as in this patient, may be life
saving. It should be undertaken, however, with circumspection.

My thanks are due to Professor S. Sherlock for permission to publish details of this case. I wish to thank Dr Enid Bennett, University College Hospital, who carried out most of the haematological investigations and helped in the preparation of the manuscript. Dr A. A. Sharp (Oxford) gave much valuable advice in the management of this patient in addition to measuring fibrin degradation products. Dr P. T. Flute, King’s College Hospital, kindly did the plasminogen assays.

References

Hardaway, R. M., Husni, E. A., Geever, E. F., Noyes, H. E., and

M. J. Whelton

Local `Shwartzman equivalent' reaction in active chronic hepatitis

Michael J. Whelton

doi: 10.1136/gut.13.1.43